Skip to content

Feasibility and acceptability of neuromuscular electrical stimulation (NMES) to improve and prevent sarcopenia in stroke patients: a pilot study

Feasibility and acceptability of neuromuscular electrical stimulation (NMES) to improve and prevent sarcopenia in stroke patients: a pilot study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0010037
Enrollment
30
Registered
2024-12-13
Start date
2024-10-02
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Experimental : The subject, while seated in a chair or wheelchair, or lying down, will undergo 30 minutes of electrical stimulation therapy by attaching the electrical stimulator to t

Sponsors

The Catholic University of Korea, Bucheon St. Mary's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Adults aged 50 or older -Patients with confirmed stroke (cerebral infarction, cerebral hemorrhage) based on brain imaging -Patients with first-ever stroke, more than 1 month since onset -Patients with unilateral paralysis and difficulty walking (FAC score 0-3) -Patients currently receiving functional neuromuscular electrical stimulation therapy for the lower limbs -Defined as having sarcopenia based on the Asian Working Group of Sarcopenia 2 (AWGS2) criteria, or classified as high-risk for sarcopenia based on the following: -Scored at least 4 out of 10 on the Sarcopenia Screening Questionnaire (SARC-F) -At risk for sarcopenia as determined by calf circumference measurement (less than 34 cm for men, less than 33 cm for women) -Patients who can express pain sensation based on the Visual Analog Scale (VAS) -Patients currently receiving rehabilitation treatment in a general hospital, university hospital, or rehabilitation specialty hospital

Exclusion criteria

Exclusion criteria: -Individuals with impaired consciousness that makes it difficult to conduct the clinical trial -Individuals with joint contractures or severe spasticity that hinder voluntary movement -Stroke affecting both cerebral hemispheres -Individuals with other neurological diseases that cause functional deterioration, such as progressive peripheral neuropathy, myopathy, or spinal cord injury -Individuals with uncontrolled internal/external diseases -Individuals showing evidence of altered consciousness, such as delirium or confusion -Individuals with uncontrolled severe pain (VAS score of 4 or higher) in major joints of the lower limbs -Individuals with uncontrolled skin lesions at the site of surface electrode attachment (thigh of the lower limb) -Individuals with implanted devices such as pacemakers, defibrillators, electric pumps, or electrical stimulators -Individuals with uncontrolled renal failure or severe systemic edema due to heart failure

Design outcomes

Primary

MeasureTime frame
Change of muscle quotient

Secondary

MeasureTime frame
bioelectrical impedance analysis;Hand grip strength;Knee extension muscle strength;Change of Modified Rankin Scale;Functional Ambulation Category;serum biomarkers;Thigh circumference measurement

Countries

Korea, Republic of

Contacts

Public ContactSUN IM

The Catholic University of Korea, Bucheon St. Mary's Hospital

hy2park@naver.com+82-32-340-2170

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026